Colossal Biosciences' FY 2026 revenue exceeds $100M
Resolves: Colossal Biosciences reports annual revenue for fiscal year 2026 (ending December 31, 2026, or its fiscal year) exceeding $100 million, as confirmed in an official financial statement or credible news report by April 15, 2027.
Colossal Biosciences' FY 2026 revenue exceeds $100M
Market overview
Colossal has started generating revenue from government contracts, spin-offs, and conservation tech. If the company's revenue growth accelerates, it may surpass $100 million for its fiscal year 2026, a milestone that would justify its high valuation.
earnings prediction market
- Implied probability (Yes)
- 30%
- Closes
- 2027-04-15
About this prediction
Resolution criteria
Colossal Biosciences reports annual revenue for fiscal year 2026 (ending December 31, 2026, or its fiscal year) exceeding $100 million, as confirmed in an official financial statement or credible news report by April 15, 2027.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes